Clinical Studies
Head: Dr. Stefan Hagel
In addition to the development of new substances, the rational use of antibiotics and stringent hygiene, isolation and sanitation measures play a decisive role in the fight against the increasing development of resistance. These are also in the focus of our clinical and scientific studies. However, the rational use of antibiotics and timely isolation require early detection and differentiation of resistant pathogens. Therefore, a large part of our projects deals with this topic. In addition to the development of innovative and faster detection methods for β-lactamases and other resistances, the effect of old antibiotics (also in combination) on multi-resistant bacteria is also investigated.
Since the pandemic SARS-Cov-2 outbreak, the institute has also been working on various issues related to the phylogeny of SARS-Cov-2 viruses and the pathophysiology and control of COVID-19.
Research Areas
Head: Dr. Daniel Schwarzkopf und Dr. Carolin Fleischmann-Struzek
Networks
The Institute of Infectious Diseases and Infection Control is also a member of CAPNETZ, the Competence Network for Ambulatory Acquired Pneumonia, and is involved in the epidemiology of pneumococci and the influence of new vaccines on it. Furthermore, we are involved as a study center in various national and international clinical studies.
Bachelor / Master Theses
We also offer the possibility of a flexible laboratory internship within the framework of our current projects. You are welcome to contact us in this regard.
Requirements: Candidates should have good basic knowledge of microbiology/molecular biology and enjoy independent, problem-oriented work. In addition, good knowledge of analysis software such as MS Excel, Origin, GraphPad or the programming language R for data analysis would be an advantage.
Contact: Please direct your questions and application to Dr. rer. nat. Oliwia Makarewicz, , Tel.: +49 3641 9-324227.